Vital Therapies, Inc. (NASDAQ:VTL) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

Several other brokerages have also recently commented on VTL. BidaskClub raised Vital Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 5th. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Vital Therapies presently has an average rating of “Hold” and an average target price of $8.00.

Shares of Vital Therapies (NASDAQ:VTL) opened at 5.75 on Friday. Vital Therapies has a 12 month low of $2.25 and a 12 month high of $6.50. The stock’s market capitalization is $242.69 million. The stock has a 50 day moving average price of $4.85 and a 200 day moving average price of $3.55.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. During the same period last year, the firm earned ($0.30) earnings per share. On average, analysts anticipate that Vital Therapies will post ($1.31) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Vital Therapies, Inc. (VTL) to “Sell”” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/21/valuengine-upgrades-vital-therapies-inc-vtl-to-sell.html.

In other Vital Therapies news, Director Muneer A. Satter bought 50,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The stock was acquired at an average price of $3.53 per share, with a total value of $176,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Muneer A. Satter bought 130,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was acquired at an average cost of $4.01 per share, with a total value of $521,300.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 190,000 shares of company stock valued at $737,800. 32.60% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after purchasing an additional 1,157 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Vital Therapies by 11.5% during the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after purchasing an additional 9,120 shares during the last quarter. Victory Capital Management Inc. boosted its position in Vital Therapies by 1.2% during the second quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after purchasing an additional 29,840 shares during the last quarter. Blair William & Co. IL boosted its position in Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after purchasing an additional 40,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Vital Therapies during the first quarter valued at $167,000. 25.58% of the stock is owned by institutional investors and hedge funds.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.